natgillin/translations-raw huggingface dataset:
Device according to embodiment 12, characterised in that there is mounted a second coil spring, preferably a tension spring, near the second piston rod, preferably parallel hereto. Device mainly as described above with reference to the drawings. 
Postupak u skladu s patentnim zahtjevom 12, naznačen time, što ovaj postupak nadalje obuhvaća fazu montiranja druge spiralne opruge, poželjno vlačne opruge, koja je u blizini drugog klipnog štapa, poželjno da je paralelna s njim.
to produce the compound and then converting the compound 12 to the compound 
(11) reakciju spoja 11 sa da se proizvede spoj i (ili) zatim konverziju spoja 12 u spoj
The attenuated virus of claim 1, wherein the modified protein encoding sequence has a codon pair bias which is reduced by at least 0.1 compared to the codon pair bias of the parent protein encoding sequence. 
Oslabljeni virus prema zahtjevu 1., naznačen time što sekvenca koja kodira modificirani protein ima pristranost para kodona koja je smanjena za barem 0,1 u usporedbi s pristranosti para kodona sekvence koja kodira matični protein.
A method of treating multiple myeloma, non small cell lung cancer, glioblastoma, or neoplasms of the prostate, breast, or ovaries comprising in a patient in need thereof comprising administering an effective amount of the compound or a pharmaceutically acceptable salt thereof, a hydrate of the compound, or a hydrate of a pharmaceutically acceptable salt of the compound of claim 1 . 
Upotreba spoja prema bilo kojem od patentnih zahtjeva 1 do 3, naznačena time što se spoj koristi za proizvodnju lijeka namijenjenog liječenju multiplog mijeloma, nemikrocelularnog raka, glioblastoma ili neoplazmi prostate, dojke ili jajnika.
R is hydrogen or methyl; 
R jest vodik ili metil;
The solution is then allowed to cool to room temperature. 
Otopina je ostavljena da se ohladi do sobne temperature.
The method of claim 15, wherein the cancer is glioma (glioblastoma), acute myelogenous leukemia, melanoma, non-small cell lung cancer (NSCLC), cholangiocarcinomas, chondrosarcoma, myelodysplastic syndromes (MDS), myeloproliferative neoplasm (MPN), or colon cancer. 
što se rak bira između glioma (glioblastoma), akutne mijelogene leukemije, melanoma, raka velikih stanica pluća (NSCLC), kolangiokarcinoma, hondrosarkoma, mijelodisplastičnog sindroma (MDS), mijeloproliferativne novotvorine (MPN), te raka debelog crijeva, koji dodatno može sadržavati drugo terapijsko sredstvo, korisno u liječenju raka.
it has an amount of G2 structures on the total carbohydrate structures or on the carbohydrate structures at one particular glycosylation site of the antibody molecule of said antibody molecules in said antibody molecule composition which is at least 5% higher compared to the same amount of antibody molecules in at least one antibody molecule composition of the same antibody molecule isolated from ATCC No. 
- ima količinu G2 struktura na ukupnim ugljikohidratnim strukturama ili na ugljikohidratnim strukturama na nekom određenom mjestu glikoziliranja u molekuli protutijela kod navedenih molekula protutijela u navedenom pripravku s molekulom protutijela koja je najmanje 5% veća u usporedbi s istom količinom molekula protutijela u pripravku s najmanje jednom molekulom protutijela za istu molekula protutijela izoliranu iz ATCC No.
A pyrazolopyrimidine compound of formula (I) wherein, Y1 represents N or C-, Y2 represents N or C-, Y3 represents N or C-, Y4 represents N or C-, whereby at least two of the groups Y1 to Y4 denote a carbon atom, R1 represents chloro or bromo; 
predstavlja N ili C-, predstavlja N ili C-, predstavlja N ili C-, pri čemu barem dvije od skupina Y1 do Y4 označavaju atom ugljika,
A combination according to claim 3 or 4, wherein the B2 agonist is selected from the group comprising formoterol, salmeterol and QAB-149 optionally in the form of their racemates, their enantiomers, their diastereomers and mixtures thereof, and optionally their pharmacologically-compatible acid addition salts. A combination according to claim 5 wherein the B2 agonist is formoterol fumarate. 
Kombinacija u skladu s patentnim zahtjevom 3, naznačena time, da je inhibitor PDE4 odabran iz skupine koju čine cilomilast, roflumilast, denbufilin i tetomilast, po izboru u obliku njihovih racemata, enantiomera, dijastereomera i mješavina navedenog te, po izboru, njihovih farmakološki kompatibilnih adicijskih soli kiselina.
a first monomer comprising: 
prvi monomer, koji sadrži:
with the exclusion of the following compound: 
sa izuzetkom sljedećeg spoja:
the peripherally outer thickness of the tapered rib is greater than a wall thickness of the edge periphery of the cutout. 
konusno rebro (212, 214) čija je periferna vanjska debljina veća od debljine stijenke (305) ostatka tijela (180, 268, 302).
The present invention provides polypeptide HP, or a polynucleotide sequence encoding polypeptide HP, or a host cell comprising said polynucleotide sequence, or a host cell comprising an expression vector comprising said polynucleotide sequence, for use in the treatment and/or prevention of a disorder in a subject; wherein said disorder is an inflammatory disorder and/or an autoimmune disorder; wherein said polypeptide has at least 75% identity to SEQ ID NO 2, SEQ ID NO 4 or SEQ ID NO 6 or variants, homologues, fragments or derivatives thereof; and wherein said polynucleotide sequence encodes a polypeptide which has at least 75% identity to SEQ ID NO 2, SEQ ID NO 4 or SEQ ID NO 6 or variants, homologues, fragments or derivatives thereof and/or wherein said polynucleotide sequence has at least 75% identity to SEQ ID NO 1, SEQ ID NO 3 or SEQ ID NO 5 or variants, homologues, fragments or derivatives thereof. 
HR P20180847 T1 PATENTNI ZAHTJEVI Polipeptid HP ili polinukleotidna sekvenca koja kodira polipeptid HP za upotrebu u liječenju i/ili prevenciji poremećaja kod subjekta; pri čemu je navedeni poremećaj upalni poremećaj i/ili autoimuni poremećaj; pri čemu navedeni polipeptid je najmanje 75% identičan sa SEQ ID NO 2, SEQ ID NO 4 ili SEQ ID NO 6 i pri čemu navedena sekvenca polinukleotida kodira polipeptid koji ima najmanje 75% identičnosti sa SEQ ID NO 2, SEQ ID NO 4 ili SEQ ID NO 6 ifili pri čemu navedena sekvenca polinukleotida ima najmanje 75% identičnosti sa SEQ ID NO 1, SEQID NO 3 ili SEQ ID NO 5.
Use of an effective amount of a conjugate molecule as defined in anyone of claims 17 to 20 or a compound of formula (I) as defined in anyone of claims 1 to 16 for the preparation of a medicament for killing or inhibiting growth of cells comprising contacting target cells or tissue containing target cells. 
Upotreba djelotvorne količine molekule konjugata u skladu s bilo kojim od patentnih zahtjeva 3 do 9 ili spoja u skladu s bilo kojim od patentnih zahtjeva 1 ili 2, u pripravi medikamenta za ubijanje ili inhibiranje rasta stanica, naznačena time što se sastoji u stavljanju u kontakt molekule konjugata ili spoja s ciljanim stanicama ili tkivom koje sadrži ciljane stanice.
adding NH4VO3 to the slurry while stirring for about 15 min; then reacting compound (III) with said catalyst slurry; in an organic solvent or mixture of solvents selected from the group consisting of xylenes and butyronitrile; under an inert atmosphere; in the presence of hydrogen gas; at a temperature of about 70 °C; to obtain compound (IV). 
Postupak prema zahtjevu 10, naznačen time što korak (2e) nadalje obuhvaća reakciju fenil tionokloroformijata s DMAP da nastane kvaternarna sol koja se može izolirati, spoj (S1), zatim, reakciju spoja (XVII) sa spojem S1; u prisutnosti organske baze koja je izabrana iz trietilamina ili DIPEA; u DMA; na temperaturi u rasponu od oko -20 °C do oko 80 °C; da se dobije odgovarajući spoj (X).
A consumable cartridge according to claim 6, further comprising a mixing chamber having a dispensing opening, the mixing chamber in fluid communication with both the first outlet and the second outlet, and configured to ensure a substantially complete reaction of vapors from the reactant supply with ozone from the ozone supply before release to the user environment through the dispensing opening. 
Potrošni uložak prema zahtjevima 3 ili 4, naznačen time da dodatno sadrži komoru za miješanje (830) koja ima otvor za doziranje, te je komora za miješanje (830) u fluidnoj vezi sa oba, prvim izlazom i drugim izlazom, te je konfiguriran kako bi se osigurala uglavnom okončana reakcija para iz zalihe reaktanta s ozonom iz zalihe ozona prije otpuštanja u korisničko okruženje kroz otvor za doziranje.
The integrated circuit according to any of claims 1 to 8, wherein, in the second allocation, Localized Virtual Resource Blocks, LVRBs, are mapped to PRBs, and the LVRBs are allocated in units of the RBGs. 
Integrirani krug sukladno jednom od zahtjeva 1 do 9, naznačen time da su u drugoj dodjeli, lokaliziram virtualni blokovi resursa, LVRB-ovi, mapirani na PRB-ove, i LVRB-ovi su dodijeljeni uređaju mobilnoj stanici u jedinicama RBG-a.
The soft chewable veterinary composition of claim 4, wherein the composition comprises: a filler selected from the group consisting of corn starch, pre-gelatinized corn starch, corn gluten meal, soy protein fines, and a combination thereof; a solvent selected from the group consisting of liquid polyethylene glycols, propylene glycol, propylene carbonate, caprylic/capric triglycerides, caprylic/capric/linoleic triglycerides, caprylic/capric/succinic triglycerides, propylene glycol dicaprylate/dicaprate, glycerol caprylate/caprate, polyglycolized glycerides, and a combination thereof; 
Mekani veterinarski pripravak za žvakanje u skladu sa zahtjevom 1, naznačen time, da pripravak obuhvaća sljedeće: a) punilo odabrano od kukuruznog škroba, predželatiniziranog kukuruznog škroba, kukuruznog glutenskog brašna i fino mljevenih sojinih proteina, ili njihove kombinacije; b) otapalo odabrano od tekućih polietilenglikola, propilenglikola, propilen-karbonata, kapriličnih/kapričkih triglicerida, kapriličnih/kapričkih/linoleinskih triglicerida, = kapriličnih/kapričkih/sukcinskih triglicerida, propilenglikol-dikaprilata/dikaprata, glicerol-kaprilata/kaprata i poliglikoliziranih glicerida, ili njihove kombinacije;
The topical veterinary composition of claim 7, wherein the at least second active agent is an anthelmintic active agent selected from thiabendazole, oxibendazole, mebendazole, fenbendazole, oxfendazole, albendazole, triclabendazole, febantel, levamisole, pyrantel, morantel, praziquantel, closantel, clorsulon, an amino acetonitrile active agent, and an aryloazol-2-yl cyanoethylamino active agent. 
Topikalni veterinarski pripravak prema zahtjevu 7, naznačen time, da najmanje druga djelatna tvar je antihelmintska djelatna tvar odabrana od tiabendazola, oksibendazola, mebendazola, fenbendazola, oksfendazola, albendazola, triklabendazola, febantela, levamisola, pirantela, morantela, prazikvantela, klozantela, klorsulona, djelatne tvari aminoacetonitrila, i djelatne tvari ariloazol-2-il-cijanoetilamina.
The composition or aerosol of any of claims 6 to 10, wherein the solution has an osmolality from about 200 mOsmol/kg to about 1250 mOsmol/kg, preferably from about 250 mOsmol/kg to about 1050 mOsmol/kg, more preferred from about 350 mOsmol/kg to about 750 mOsmol/kg. 
Smjesa ili aerosol iz bilo kojeg od patentnih zahtjeva 6 do 10, pri čemu rastvor ima osmolarnost od oko 200 mOsmol/kg do oko 1250 mOsmol/kg, preporučljivo od oko 250 mOsmol/kg do oko 1050 mOsmol/kg, još preporučljivije od oko 350 mOsmol/kg do oko 750 mOsmol/kg.
adjusting Cch l and of Clan l so as to obtain Clan l = 0 and to obtain Cch l = Ct ch l, wherein Ct ch l is the target concentration of the free macrocyclic chelate in the final liquid pharmaceutical formulation and is selected in the range of between 0.002 % and 0.4 % mol/mol, said adjustment of Cch l and of Clan l being performed if Clan l > 0 and/or Cch l < Ct ch l, by adding free macrocyclic chelate and/or by eliminating free lanthanide by passing through an ion-exchange resin and/or by modifying the pH, 
podešavanje Cch 1 i Clan 1 pomoću dodavanja u formulaciju dobivenu u koraku b) potrebne količine slobodnog makrocikličkog kelata, prvo, da se okonča kompleksiranje slobodnog lantanida tako da se dobije Clan 1 = 0, te drugo, da se dobije Cch 1 = Ct ch 1, pri čemu Ct ch 1 je ciljana koncentracija slobodnog makrocikličkog kelata u konačnoj tekućoj farmaceutskoj formulaciji, te je odabrana u rasponu od između 0.002 % i 0.4 % mol/mol, pri čemu količina slobodnog makrocikličkog kelata u konačnoj tekućoj farmaceutskoj formulaciji odgovara udjelu slobodnog makrocikličkog kelata u odnosu na količinu kompleksiranog makrocikličkog kelata u konačnoj tekućoj farmaceutskoj formulaciji.
A compound according to claim 60, wherein in formula (2-a) R1 is hydrogen or a nitrogen protecting group selected from pivaloyl and t-butyloxycarbonyl (BOC). 
Spoj prema zahtjevu 60, naznačen time, da u formuli (2-a), RI je vodikova ili dušikova zaštitna skupina odabrana od pivaloila i t-butiloksikarbonila (BOC).
Preparing the dermal matrix system (11), 
pripravljanja sustava dermalnog matriksa (11),
when R2 represents a group of formula (Ia), reacting a compound of formula (II) 
(a) kada R* predstavlja skupinu sa formulom (Ia), reakciju spoja sa formulom(II)
The prior art processes enable the production of crystals using flow rate ratios of anti-solvent: solvent that are generally lower than 20:1 (i.e. towards a flow rate ratio of 10:1 to as low as 1:1). SUMMARY OF THE INVENTION According to the present invention there is provided a process for preparing an emulsion or a dispersion comprising crystalline particles of at least one active principal that comprises contacting a saturated solution of at least one solute in a solvent in a first flowing stream with a non-solvent in a second flowing stream wherein the non-solvent and solvent are not miscible with each other, forming an emulsion or a dispersion wherein the said solute is present in a super-saturated solution within the droplets of the emulsion or dispersion so formed, and subjecting the emulsion or dispersion to ultrasonic irradiation. 
Postupak za pripremu kristalnih čestica od barem jedne aktivne osnove koji obuhvaća dolazak u dodir zasićene otopine barem jedne otopljene tvari u otapalu u prvom tekućem mlazu s ne-otapalom u drugom tekućem mlazu pri čemu je omjer protoka drugi tekući mlaz: prvi tekući mlaz najmanje 20:1, a ne-otapalo i otapalo se ne miješaju međusobno i ne-otapalo sadrži surfaktant ili dispergant, tvoreći emulziju ili disperziju kapljica, pri čemu navedena otopljena tvar postaje super-zasićena tako nastalim kapljicama emulzije ili disperzije, i podvrgavanje emulzije ili disperzije ultrazvučnom zračenju, pri čemu je barem jedna otopljena tvar aktivna osnova ili njen prekursor, ultrazvuk inducira nukleaciju 1 tako kristalizaciju barem jedne otopljene tvari; recirkuliranje ne-otapala i otopljene tvari u mlazu stalne recirkulacije; i posljedično izoliranje koje rezultira kristalnim česticama.
a photoreceptor cell, a retinal rod cell, a retinal cone cell, a retinal ganglion cell, a bipolar neuron, a ganglion cell, a pseudounipolar neuron, a multipolar neuron, a pyramidal neuron, a Purkinje cell, or a granule cell; or 
stanica fotoreceptor, štapićasta stanica retine, čunjasta stanica retine, ganglijska stanica retine, bipolarni neuron, ganglijska stanica, pseudounipolarni neuron, multipolarni neuron, piramidalni neuron, Purkinjeova stanica, ili granulirana stanica; ili
The harness preferably includes connector means to which e.g. a retention strap is connectable and from which the strap may extend across a part of the head of a user thereby to strap an aforesaid headwear member to the head of the user. Most preferably the strap connector means is defined by a portion of the harness shaped to be raised and separated from the surface of the headwear member when the harness is fitted thereto, thereby to enable an article (e.g. the strap) to pass between the strap connector means and the surface of the headwear member over which the connector means is raised thereby to permit attachment of the strap thereto. 
Slušalice prema bilo kojem od zahtjeva 23 do 25, naznačene time, da navedena tehnička oprema obuhvaća konektor na koji se može spojiti zadržna pasica, te s kojega se navedena pasica može protezati preko dijela glave korisnika, čime pripasuje navedenu školjku za uho na glavu korisnika, dok je konektor definiran pomoću dijela tehničke opreme oblikovanog tako, da se uzdiže 1 odvaja od površine školjke za uho, kada je za nju pričvršćena tehnička oprema, čime se omogućava navedenoj pasici da prolazi između konektora pasice i površine školjke za uho preko koje se konektor uzdiže, a time se dopušta priključenje navedene pasice.
Use according to claim 1, characterized in that said 2-((1-methylpropyl)amino)ethanol additive is added as a water based solution to the calcium carbonate-comprising material. 
2. Postupak u skladu s patentnim zahtjevom 1, naznačen time da je navedeni aditiv 2-((1-metilpropil)aminojetanol dodan kao otopina na bazi vode materijalu koji sadrži kalcijev karbonat.
On its outer surface, said container 151 is provided laterally with male means 155 for coupling with corresponding female means 128 that are provided on the inner vertical surfaces of the horizontal arm 121 of the box-shaped base member 110 (see FIG. 3). 
Na svojoj vanjskoj površini navedeni spremnik 151 ima sa strane muške priključke 155, za povezivanje s odgovarajućim ženskim priklučcima 128, smještenim na unutarnjim okomitim površinama vodoravnog kraka 121 kutijastog osnovnog elementa 110 (vidjeti Sliku 3).
The use of the adhesive layer 14 based on vegetable starches and glucose, in addition to performing in an optimum manner the function of making the third aluminum layer 13 and the first paper layer 11 adhere intimately by using only natural substances suitable for possible contact with food products, allows during disposal of the sheet 10 to separate easily the first layer 11 from the second layer 12 and the third layer 13. 
Upotreba sloja ljepila 14 na osnovi biljnih škrobova i glukoze omogućuje na optimalan način provedbu funkcije da pri izradi trećeg alumijskog sloja 13 i prvog papirnatog sloja 11 oni tijesno prijanjaju upotrebom samo prirodnih tvari prikladnih za mogući dodir s proizvodima za hranu, i dodatno tijekom odbacivanja folije 10 upotreba sloja ljepila 14 omogućuje lako rastavljanje prvog sloja 11 od drugog sloja 121 trećeg sloja 13.
wherein sALP is the extracellular domain of the alkaline phosphatase; wherein V is absent or is an amino acid sequence of at least one amino acid; 
Z-SsALP- Y-razmak-X-Wn-V, naznačena time da sALP je izvanstanična domena alkalne fosfataze; pri čemu V je odsutan ili je aminokiselinski slijed sa barem jednom aminokiselinom;
In that case the lactide content of the PLGA is of at least 85% and the inherent viscosity is between 0.1 and 0.4 dl/g. 
Farmaceutski pripravak prema zahtjevu 1, gdje taj kopolimer u prvoj skupini obuhvaća najmanje 85% (molarno) mliječne kiseline i ima inherentnu viskoznost između 0.55 i 0.75 dl/g.
A pharmaceutical composition according to any one of claims 1 to 5, wherein said meglumine, if present, is: free meglumine or a pharmaceutically acceptable salt of meglumine. 
Farmaceutski sastav prema zahtjevu 1 ili 2, naznačen time, da spomenuti arginin je slobodni L-arginin ili farmaceutski prihvatljiva sol od L-arginina.
introducing an isobutylamino group in compound of formula (1'); to obtain compound of formula (2'); 
(i) uvođenje izobutilamino skupine u spoju formule (1); pa LO CA AL kako bi se dobio spoj formule (2*); s a:
The system of the present invention works by generating commands that have the same effect, on the components of the boat, as the commands produced by operation of the conventional controls. 
Sustav opisanog izuma radi tako da generira komande koje imaju jednaki učinak na komponente plovila, kao i komande koje nastaju djelovanjem konvencionalnih kontrola.
providing a population of human definitive endoderm (DE) cells, and culturing said population of human DE cells on a support coated with a laminin in a hepatic induction medium to produce a population of human hepatoblast-like cells, and 
(i) uzgoj populacije ljudskih DE stanica na podlozi koja je obložena ljudskim lamininom u jetrenom indukcijskom mediju kako bi se proizvela populacija ljudskih hepatoblastno-sličnih stanica, i (ii) uzgoj navedene populacije ljudskih hepatoblastno-sličnih stanica na podlozi koja je obložena s ljudskim lamininom u mediju za sazrijevanje jetre kako bi se proizvela populacija ljudskih fetalnih hepatocitno-sličnih stanica.
adding to the reaction mixture hydrogen peroxide, and optionally a reagent selected from the group of acetate salts, butyrate salts, and salts of alpha-hydroxy acids, and combinations thereof; 
(ii) dodavanje u reakcijsku smjesu vodikovog peroksida, te proizvoljno reagensa odabranog iz skupine koja sadrži soli acetata, soli butirata, te soli alfa-hidroksi kiselina, i njihove kombinacije;
A host cell as defined in claim 1, wherein the first vector encodes a light chain of SEQ ID NO: 64 and the second vector encodes a heavy chain of SEQ ID NO:62. 
Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što sadrži teški lanac sa SEQ ID NO:62 i laki lanac sa SEQ ID NO:64.
The use of any one of the preceding items, wherein said patient is a human. 
Glukokortikoid za uporabu iz bilo kojeg od prethodnih patentnih zahtjeva, pri čemu je navedeni pacijent čovjek.
The pharmaceutical composition for use of claim 9, wherein the micellar particle increases the production of anti-G protein antibodies in a host. 
Postupak sukladno patentnom zahtjevu 1, da je micela sposobna povećati proizvodnju antitijela protiv G proteina u domaćinu.
Excipients that may function as glidants include, but are not limited to, colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, starch, talc and tribasic calcium phosphate. 
Pomoćne tvari koje mogu djelovati kao sredstva za klizanje uključuju, ali bez ograničavanja, koloidni silicijev dioksid, magnezijev trisilikat, prah celuloze, škrob, talk i trobazni kalcijev fosfat.
wherein in each peptide monomer of the peptide dimer, each amino acid is indicated by standard one letter abbreviation, AcG is N-acetylglycine, 1-nal is 1-naphthylalanine, and MeG is N-methylglycine; 
(i) u svakom peptidnom monomeru peptidnog dimera svaka aminokiselina je označena standardnom jednoslovnom kraticom, AcG je N-acilglicin, 1-nal je 1-naftilalanin, a MEG je N-metilglicin;
The compound according to claims 1-12 wherein R6-R10 are H with the proviso that one of the groups R7, R8 or Rg is the sulfonyl group with R1. 
Spoj prema zahtjevima 1-12, naznačen time što R4-Ry su H s uvjetom da je jedna od skupina R;, Rg ili Ro sulfonil skupina s Ri.
The use of opioid antagonists according to claim 1 wherein the opioid antagonist such as naltrexone, naloxone or nalmefene is administred to the patient in an oral dosage form comprising a tablet, coated tablets, chewable tablets, dispersable tablets, rapid dissolve tablets, sublingual tablets, effervescent tablets, effervescent granules, dragees, capsules, sachets, cachets, caplets, lozenges, liposomes, powders, granules, powders for suspensions, powders for solutions, solutions, emulsions, liquids and syrups. 
Uporaba opioidnih antagonista prema zahtjevu 1 naznačena time da se opioidni antagonist kao što je naltrekson, nalokson ili nalmefen daje pacijentu u oralnom obliku doziranja koji čini tableta, obložene tablete, tablete za žvakanje, raspršive tablete, brzo topive tablete, sublingvalne tablete, šumeće tablete, šumeće granule, dražeje, kapsule, vrećice, škrobne kapsule, kaplete, pastile, liposomi, prašci, granule, prašci za suspenzije, prašci za otopine, otopine, emulzije, tekućine 1 sirupi.
The building panels according to claim 12, wherein the building panels have a fold down locking system on the short edges with a flexible tongue that allows locking with vertical folding. 
Podne ploče prema bilo kojem od prethodnih zahtjeva, naznačene time da podne ploče imaju preklopni sustav za zaključavanje na kratkim rubovima (lc, 1d) s fleksibilnim jezičeem (10) koji omogućuje zaključavanje vertikalnim preklapanjem.